Sagar Bhagwat, MBA, MS

CRS:

BJMC

Role:

Administrative and Finance

Position:

Senior Grants and Contracts Analyst

Mr. Bhagwat is the Senior Grants and Contracts Analyst for Johns Hopkins Center for Clinical Global Health Education (CCGHE) and manages the financial activities of the center along with the Fiscal Operations Manager. He works on all aspects of sponsored research pre and post award, including development and management of federal, state, private, and foundation grants/contracts. He is the primary contact for all outgoing CCGHE subcontracts and works closely with international collaborators in India, Uganda, United Kingdom as well as domestic collaborators within the US.
 
Mr. Bhagwat is a part of the CCGHE leadership group that provides financial/administrative support and oversight to the Johns Hopkins entities in India (Johns Hopkins India Pvt. Ltd & Johns Hopkins India Foundation). He works closely with external funding agencies such as US National Institutes of Health (NIH), CRDF Global, Maryland Department of Health (MDH) among others and internally with the Office of Research Administration (ORA), the Office of Sponsored Projects and Shared Services (SPSS), the Department Finance Office at the Johns Hopkins University School of Medicine.
 
He joined Johns Hopkins in 2016 with several years of accounting and finance experience. He received a dual Master’s degree in Business Administration (MBA in Operations Management) and Science (MS in Chemical & Biomedical Engineering) from the Cleveland State University.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More